European Commission (EC) approves Minjuvi with lenalidomide for the treatment of large B-cell lymphoma in adults.
List view / Grid view
New data shows Lilly’s Olumiant (baricitinib) significantly reduces the risk of death in hospitalised COVID-19 patients receiving invasive mechanical ventilation or ECMO.
New Phase III data shows once daily treatment with baricitinib significantly increases hair regrowth in adult patients with severe alopecia areata.
A study of baricitinib in combination with remdesivir has met its primary endpoint in COVID-19 patients, by reducing time to recovery in comparison with only remdesivir.